戴维医疗
(300314)
| 流通市值：19.84亿 | | | 总市值：30.18亿 |
| 流通股本：1.89亿 | | | 总股本：2.88亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 155,328,964.53 | 618,298,238.74 | 458,961,630.27 | 317,308,737.59 |
| 营业收入 | 155,328,964.53 | 618,298,238.74 | 458,961,630.27 | 317,308,737.59 |
| 利息收入 | - | 0 | - | - |
| 已赚保费 | - | 0 | - | - |
| 手续费及佣金收入 | - | 0 | - | - |
| 二、营业总成本 | 108,971,100.08 | 471,574,505.83 | 343,186,055.45 | 229,652,952.21 |
| 营业成本 | 64,421,182.5 | 258,478,134.3 | 192,653,037.88 | 129,765,845.88 |
| 利息支出 | - | 0 | - | - |
| 手续费及佣金支出 | - | 0 | - | - |
| 退保金 | - | 0 | - | - |
| 赔付支出净额 | - | 0 | - | - |
| 保单红利支出 | - | 0 | - | - |
| 分保费用 | - | 0 | - | - |
| 税金及附加 | 1,035,494.63 | 8,853,445.6 | 5,651,111.17 | 4,469,874.25 |
| 销售费用 | 22,670,944.08 | 121,920,460.25 | 92,293,397.97 | 63,870,825.74 |
| 管理费用 | 13,296,577.44 | 54,206,836.26 | 42,019,929.4 | 28,808,864.16 |
| 研发费用 | 10,287,345.11 | 48,059,212.59 | 27,448,854.17 | 17,114,449.96 |
| 财务费用 | -2,740,443.68 | -19,943,583.17 | -16,880,275.14 | -14,376,907.78 |
| 其中:利息费用 | 132,751.17 | 598,807.42 | 450,393.91 | 312,328.02 |
| 其中:利息收入 | 2,802,839.84 | 14,540,986.45 | 10,566,329.89 | 7,059,704.04 |
| 加:公允价值变动收益 | - | 263,863.02 | - | - |
| 加:投资收益 | -2,554,623.67 | 11,328,629.48 | 10,825,202.75 | 9,938,222.29 |
| 汇兑收益 | - | 0 | - | - |
| 资产处置收益 | -43,673.56 | -228,115.57 | -281,465.8 | -285,953.66 |
| 资产减值损失(新) | - | -2,690,137.06 | - | - |
| 信用减值损失(新) | -652,079.94 | -472,598.94 | -1,135,584.87 | -610,920.92 |
| 其他收益 | 1,381,449.45 | 16,439,286.12 | 13,982,636.85 | 7,328,962.04 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 44,488,936.73 | 171,364,659.96 | 139,166,363.75 | 104,026,095.13 |
| 加:营业外收入 | 82,130.68 | 155,550.22 | 42,034.74 | 24,495.89 |
| 减:营业外支出 | 140,875.84 | 5,295,485.41 | 192,372.1 | 150,999.66 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 44,430,191.57 | 166,224,724.77 | 139,016,026.39 | 103,899,591.36 |
| 减:所得税费用 | 6,322,962.81 | 18,613,813.26 | 16,220,715.34 | 12,122,792.16 |
| 六、净利润 | 38,107,228.76 | 147,610,911.51 | 122,795,311.05 | 91,776,799.2 |
| 持续经营净利润 | 38,107,228.76 | 147,610,911.51 | 122,795,311.05 | 91,776,799.2 |
| 归属于母公司股东的净利润 | 38,107,228.76 | 147,610,911.51 | 122,795,311.05 | 91,776,799.2 |
| (一)基本每股收益 | 0.13 | 0.51 | 0.43 | 0.32 |
| (二)稀释每股收益 | 0.13 | 0.51 | 0.43 | 0.32 |
| 八、其他综合收益 | - | 0 | - | - |
| 归属于母公司股东的其他综合收益 | - | 0 | - | - |
| 九、综合收益总额 | 38,107,228.76 | 147,610,911.51 | 122,795,311.05 | 91,776,799.2 |
| 归属于母公司股东的综合收益总额 | 38,107,228.76 | 147,610,911.51 | 122,795,311.05 | 91,776,799.2 |
| 归属于少数股东的综合收益总额 | - | 0 | - | - |
| 公告日期 | 2024-04-20 | 2024-04-09 | 2023-10-25 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |